Cargando…

Questioning Tocilizumab Use in Hospitalized Patients With Coronavirus Disease 2019

Detalles Bibliográficos
Autores principales:	Mombrun, Martin, Valette, Xavier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American College of Chest Physicians. Published by Elsevier Inc. 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8097314/ https://www.ncbi.nlm.nih.gov/pubmed/33965141 http://dx.doi.org/10.1016/j.chest.2020.11.069

Ejemplares similares

Risk Factors for Mortality in Hospitalized Coronavirus Disease 2019 Patients
por: Dietl, Beatriz, et al.
Publicado: (2020)

A trial of pirfenidone in hospitalized adult patients with severe coronavirus disease 2019
por: Zhang, Fengqin, et al.
Publicado: (2022)

A More Accurate Measurement of the Burden of Coronavirus Disease 2019 Hospitalizations
por: Vu, Christina, et al.
Publicado: (2022)

Famotidine and Coronavirus Disease 2019
por: Freedberg, Daniel E., et al.
Publicado: (2021)

Is There Still a Place for Tocilizumab in Coronavirus Disease 2019?
por: Klopfenstein, Timothée, et al.
Publicado: (2021)

Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019
por: Melody, Megan, et al.
Publicado: (2020)

Famotidine and Mortality in Coronavirus Disease 2019
por: Sethia, Rahul, et al.
Publicado: (2021)

Asthma and prognosis of coronavirus disease 2019
por: Özdemir, Öner
Publicado: (2022)

Etoposide for Cytokine Storm Because of Coronavirus Disease 2019
por: Delgado-López, Pedro David, et al.
Publicado: (2021)

Left Ventricular Systolic Function and Inpatient Mortality in Patients Hospitalized with Coronavirus Disease 2019 (COVID-19)
por: Faridi, Kamil F., et al.
Publicado: (2020)

Hospitalized coronavirus disease-2019 (COVID-19) patients with gastrointestinal symptoms have improved survival to discharge
por: Renelus, Benjamin D., et al.
Publicado: (2020)

Efficacy and safety of hospital-based group medical quarantine for dialysis patients exposed to coronavirus disease 2019
por: Zuo, Li, et al.
Publicado: (2022)

Questions about comparative genomics of SARS coronavirus isolates
por: Wood, Lowell
Publicado: (2003)

Split-dosing of coronavirus disease 2019 vaccines
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

MicroCLOTS pathophysiology in coronavirus disease 2019
por: Renzi, Samuele, et al.
Publicado: (2023)

Clinical characteristics of 1327 patients with coronavirus disease 2019 (COVID-19) in the largest Fangcang shelter hospital in Wuhan
por: Lu, Chong, et al.
Publicado: (2021)

Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes
por: Price, Christina C., et al.
Publicado: (2020)

Gut Microbiome Metabolism Drives the Resolution of Patients With Coronavirus Disease 2019
por: Zhang, Yu-Hang, et al.
Publicado: (2022)

Experience Using Paxlovid for Patients With Coronavirus Disease 2019 in a Resource-Limited Emergency Department
por: Nene, Rahul V., et al.
Publicado: (2022)

Letter to the Editor: Autoimmune Hepatitis and Coronavirus Disease 2019: Disease Outcomes and Tacrolimus Use
por: Ng, Alexander Clevewood
Publicado: (2021)

Monitoring neutrophil-to-lymphocyte ratio in patients with coronavirus disease 2019 receiving tocilizumab
por: Hartog, Nicholas L., et al.
Publicado: (2021)

A Propensity-Matched Cohort Study of Tocilizumab in Patients With Coronavirus Disease 2019
por: Lewis, Tyler C., et al.
Publicado: (2020)

Ivermectin for Coronavirus Disease 2019: Yet to Be Well Evaluated Before Clinical Use
por: Hagiya, Hideharu, et al.
Publicado: (2021)

Immune response after vaccination using inactivated vaccine for coronavirus disease 2019
por: Sun, Ya, et al.
Publicado: (2023)

Management Issues of Sarcoidosis in the Time of Coronavirus Disease 2019
por: Tana, Claudio, et al.
Publicado: (2021)

Zinc and Coronavirus Disease 2019: Causal or Casual Association?
por: Khurana, Alkesh Kumar, et al.
Publicado: (2021)

Coronavirus disease 2019 presenting with conjunctivitis as the first symptom
por: Casalino, Giuseppe, et al.
Publicado: (2020)

Exacerbation of livedoid vasculopathy after Coronavirus disease 2019
por: Kawabe, Ryoko, et al.
Publicado: (2022)

Effective strategies to prevent in-hospital infection in the emergency department during the novel coronavirus disease 2019 pandemic
por: Kung, Chia-Te, et al.
Publicado: (2021)

Drug-induced liver injury following the use of tocilizumab or sarilumab in patients with coronavirus disease 2019
por: Gao, Qian, et al.
Publicado: (2022)

Tocilizumab for coronavirus disease 2019 in pregnancy and lactation: a narrative review
por: Jorgensen, Sarah C.J., et al.
Publicado: (2022)

Comparison of Anakinra and Tocilizumab in Anticytokine Therapy in the Treatment of Coronavirus Disease-2019
por: Ozkan, Feyza, et al.
Publicado: (2022)

Letter to the Editor: Reply to Autoimmune Hepatitis and Coronavirus Disease 2019: Disease Outcomes and Tacrolimus Use
por: Efe, Cumali, et al.
Publicado: (2021)

Coronavirus disease 2019 (COVID‐19) vaccination in patients with cirrhosis: Does it work?
por: Calleri, Alberto, et al.
Publicado: (2022)

Is genetic counseling necessary for pregnant women with coronavirus infection? An unresolved question
por: Peivandi, Salome
Publicado: (2021)

Tocilizumab for severe COVID-19 pneumonia
por: Mourad, Jean-Jacques, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Lipworth, Brian J, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Piano, Salvatore, et al.
Publicado: (2020)

Airborne transmission of coronavirus disease 2019: a clinician’s perspective
por: Oh, Myoung-don
Publicado: (2021)

The many faces of coronavirus disease 2019: COVID-19 and the liver
por: Almas, Talal, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_05qdc9t1slu5kh9uv17pa5tftc